Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Proteogenomic analysis reveals cytoplasmic sequestration of RUNX1 by the acute myeloid leukemia–initiating CBFB::MYH11 oncofusion protein
Ryan B. Day, … , Christopher A. Miller, Timothy J. Ley
Ryan B. Day, … , Christopher A. Miller, Timothy J. Ley
Published December 7, 2023
Citation Information: J Clin Invest. 2024;134(4):e176311. https://doi.org/10.1172/JCI176311.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 2

Proteogenomic analysis reveals cytoplasmic sequestration of RUNX1 by the acute myeloid leukemia–initiating CBFB::MYH11 oncofusion protein

  • Text
  • PDF
Abstract

Several canonical translocations produce oncofusion genes that can initiate acute myeloid leukemia (AML). Although each translocation is associated with unique features, the mechanisms responsible remain unclear. While proteins interacting with each oncofusion are known to be relevant for how they act, these interactions have not yet been systematically defined. To address this issue in an unbiased fashion, we fused a promiscuous biotin ligase (TurboID) in-frame with 3 favorable-risk AML oncofusion cDNAs (PML::RARA, RUNX1::RUNX1T1, and CBFB::MYH11) and identified their interacting proteins in primary murine hematopoietic cells. The PML::RARA- and RUNX1::RUNX1T1-TurboID fusion proteins labeled common and unique nuclear repressor complexes, implying their nuclear localization. However, CBFB::MYH11-TurboID–interacting proteins were largely cytoplasmic, probably because of an interaction of the MYH11 domain with several cytoplasmic myosin-related proteins. Using a variety of methods, we showed that the CBFB domain of CBFB::MYH11 sequesters RUNX1 in cytoplasmic aggregates; these findings were confirmed in primary human AML cells. Paradoxically, CBFB::MYH11 expression was associated with increased RUNX1/2 expression, suggesting the presence of a sensor for reduced functional RUNX1 protein, and a feedback loop that may attempt to compensate by increasing RUNX1/2 transcription. These findings may have broad implications for AML pathogenesis.

Authors

Ryan B. Day, Julia A. Hickman, Ziheng Xu, Casey D.S. Katerndahl, Francesca Ferraro, Sai Mukund Ramakrishnan, Petra Erdmann-Gilmore, Robert W. Sprung, Yiling Mi, R. Reid Townsend, Christopher A. Miller, Timothy J. Ley

×

Figure 3

CBFB and CBFB::MYH11 have distinct protein interactomes.

Options: View larger image (or click on image) Download as PowerPoint
CBFB and CBFB::MYH11 have distinct protein interactomes.
(A) Heatmap sho...
(A) Heatmap showing DIPs with increased detection in CBFB-TurboID fusion samples (n = 12), relative to TurboID alone (n = 23); proteins detected with the CBFB::MYH11-TurboID fusion protein are plotted passively. (B) Volcano plot of proteins identified in A, with selected DIPs labeled. (C) Percentage of proteins in selected nuclear complexes with increased interaction with CBFB-TurboID fusion relative to TurboID alone. (D) Heatmap showing DIPs with increased detection in CBFB::MYH11-TurboID fusion samples (n = 8) relative to TurboID-alone samples, with CBFB-TurboID samples passively plotted. (E) Heatmap showing DIPs between CBFB-TurboID and CBFB::MYH11-TurboID fusion proteins. (F) Volcano plot of DIPs between CBFB- and CBFB::MYH11-TurboID fusions, with key differential interactors labeled. Myosin-related proteins exclusively interact with CBFB::MYH11, while CBFB interacts predominantly with nuclear proteins. (G and H) Gel images of ProteinSimple Jess blot on streptavidin beads from HSPCs expressing the indicated TurboID fusions using an antibody against MYO18A (G) or NCOR2 (H). Note pull-down of MYO18A in CBFB::MYH11-TurboID fusion, and NCOR2 pull-down in RUNX1::RUNX1T1-TurboID fusion. (I and J) ToppFun pathway enrichment for CBFB-TurboID versus CBFB::MYH11-TurboID DIPs enriched in CBFB-TurboID (I) or CBFB::MYH11-TurboID (J). Ratio indicates number of genes identified as DIPs divided by number of genes in gene set. Circle size indicates number of proteins identified. FDR, Benjamini-Hochberg FDR.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 3 X users
13 readers on Mendeley
See more details